Anti-Infliximab Antibodies Led to Poorer Clinical Outcomes

Findings from a EULAR 2023 study reveal that the development of neutralizing anti-drug antibodies during infliximab induction and maintenance therapy contributes to poorer clinical outcomes. Listen to Marthe Kirkesæther Brun from the Department of Rheumatology at the Diakonhjemmet Hospital in Norway as she presents these results and explains the promising aspect of early detection of anti-drug antibodies through proactive TDM.